Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 12Pharmaceutical Economics and PolicyGlobal Public Health Policies and EpidemiologyHealthcare Systems and Reforms

The DOI matches its Crossref record.

Drug price control in Malaysia: a stakeholder analysis

Ashraf, Amirul, Ong, Siew Chin·2021·International Journal of Health Governance
DOI 10.1108/ijhg-02-2021-0014
Open this paper in CoChat — free account

Abstract

Purpose Pharmaceutical pricing has always been a contentious issue around the world. Recently, the Government of Malaysia has proposed for drug price control. This proposal has received backlash from pharmaceutical industry. Therefore in this study, the authors would like to examine the position of various stakeholders on this issue. Design/methodology/approach The authors used Policy Maker software to identify and evaluate the position of the stakeholders, their interest and their power. Next, the authors contextualize the factors that might contribute to the success or failure of the policy using Kingdon's multiple stream analysis. Findings The authors found that the drug price control regulation received mixed reactions from the stakeholders, with the public sector mainly supporting the proposal whereas the private sectors opposing it. The findings indicate that the drug price control proposal have a high chance of success due to strong political will from both the government and the opposition and also strong support from the public and the consumer groups. Practical implications 1. The drug price control proposal received strong political will and strong public support. Thus, it has a high chance of success. 2. The government should be careful in managing concentrated powerful groups. The government should strategically engage with the stakeholders to move them to more positive attitude. 3. The government should avoid backtracking on policies as this will portray critica…

Overview

Integrity signals

Registry

Crossref · 10.1108/ijhg-02-2021-0014

Cites

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Citations

Cites

Still being checked.

Research works printed but not linked: 37

  1. 2003, Pelobian Polisi Awam: Pengaruh Gabungan Persatuan-persatuan Pengguna Malaysia (FOMCA) sebagai Kumpulan Pendesak, Jurnal Komunikasi: Malaysian Journal of Communication, 19, 39
  2. 2018, Affordability of essential medicine prices in Malaysia's private health sector, Patient Prefer Adherence, 12, 1
  3. Babar, Z.U.D., Ibrahim, M.I.M., Singh, H., Bukahri, N.I. and Creese, A. (2007), “Evaluating drug prices, availability, affordability, and price components: implications for access to drugs in Malaysia”, in Harvey, K. (Ed.), PLoS Med, [Internet], Vol. 4 No. 3, p. e82, available at: https://dx.plos.org/10.1371/journal.pmed.0040082. · DOI
  4. 2017, High drug prices: so who is to blame?, Hospital Pharmacy, 52, 5, 10.1310/hpj5201-5 · DOI
  5. 2019, The hepatitis C infection in Iran: a policy analysis of agenda-setting using Kingdon's multiple streams framework, Health Research Policy and System, 17, 1
  6. Bernama, 2020, Kumpulan isi rumah B40, M40, T20 terbahagi pada 10 kategori, Berita Harian
  7. 2020, Policy transfer processes and renewable energy penetration: a comparative analysis of Peru, Thailand, and Uganda, Sustain Earth, 3, 2, 10.1186/s42055-019-0019-4 · DOI
  8. 2012, Ambiguity: the challenge of knowing and deciding together, Environmental Science and Policy
  9. 2013, Why do ideas succeed and fail over time? The role of narratives in policy windows and the case of the London congestion charge, Journal of European Public Policy, 20, 1139, 10.1080/13501763.2013.771090 · DOI
  10. 2019, How interest groups influence public opinion: arguments matter more than the sources, European Journal of Political Research, 58, 514, 10.1111/1475-6765.12298 · DOI
  11. European Federation of Pharmaceutical Industries and Associations, 2019, The Pharmaceutical Industry in Figures
  12. 2015, Shaping the health policy agenda: the case of safe motherhood policy in Vietnam, International Journal of Heal Policy Management, 4, 741
  13. 2007, Defining strategic communication, International Journal of Strategic Communication, 1, 3, 10.1080/15531180701285244 · DOI
  14. 2012, A study comparing the retail drug prices between Northern Malaysia and Australia, Journal of Pharmaceutical Health Service Research, 3, 103, 10.1111/j.1759-8893.2011.00080.x · DOI
  15. 2010, Explaining local policy choices: a multiple streams analysis of municipal emergency management, Canadian Public Administration, 53, 241, 10.1111/j.1754-7121.2010.00128.x · DOI
  16. 2002, Agenda-setting for the regulation of traditional Chinese medicine in Hong Kong, Asian Journal of Public Administration, 24, 257, 10.1080/02598272.2002.10800403 · DOI
  17. 2020, Does external reference pricing deliver what it promises? Evidence on its impact at national level, The European Journal of Health Economics, 21, 129, 10.1007/s10198-019-01116-4 · DOI
  18. 1995, Agendas, alternatives and public policies (ch. 8)
  19. 2020, Profitability of large pharmaceutical companies compared with other large public companies, JAMA, 323, 834, 10.1001/jama.2020.0442 · DOI
  20. LIAM,PIAM M (2019), “A joint-press statement by the life insurance association of Malaysia (LIAM), Persatuan Insurans Am Malaysia (PIAM) and Malaysian Takaful Association (MTA)”, [Internet], available at: https://piam.org.my/joint-press-statement-life-insurance-association-malaysia-liam-persatuan-insurans-malaysia-piam-malaysian-takaful-association-mta/.
  21. 2018, Expanding evaluation to progress strategic communication: beyond message tracking to open listening, International Journal of Strategic Communication, 12, 469, 10.1080/1553118X.2018.1450255 · DOI
  22. Malaysia Competition Commission, 2017, Market Review on Priority Sector under Competition Act 2010 Pharmaceutical Sector
  23. 2007, Window of opportunity for intersectoral health policy in Sweden open, half-open or half-shut?, Health Promotion International, 22, 307, 10.1093/heapro/dam028 · DOI
  24. Ministry of Health Malaysia, 2019, Malaysia National Health Accounts: Health Expenditure Report 1997-2017
  25. Ministry of Health Malaysia, 2020, Ministry of Health Vision, Mission, Objectives & Role
  26. 2017, Policy entrepreneurs and problem framing: the case of climate change, Environment and Planning C: Politics and Space, 35, 1362, 10.1177/2399654417708440 · DOI
  27. PhAMA (2019), “Medicines price control will have negative repercussions”, available at: https://www.malaysiakini.com/letters/494410.
  28. 1996, PolicyMaker: Computer-Assisted Political Analysis (Software and Manual)
  29. 2015, Overview of external reference pricing systems in Europe, Journal of Market Access and Health Policy, 3, 27675, 10.3402/jmahp.v3.27675 · DOI
  30. 2017, Setting performance-based financing in the health sector agenda: a case study in Cameroon, Globalization and Health, 13, 52, 10.1186/s12992-017-0278-9 · DOI
  31. 2019, Cabinet Approves Drug Price Controls
  32. 2019, Competition Beats Medicine Price Controls
  33. The Galen Centre for Health and Social Policy, 2019, Drug Price Controls in Malaysia: Implications and Considerations
  34. WHO Regional Office for South-East Asia, 2017, Financial Protection in the South-East Asia Region: Determinants and Policy Implications, 19
  35. 2020, Lobbying expenditures and campaign contributions by the pharmaceutical and health product industry in the United States, 1999-2018, JAMA Internal Medicine, 180, 688, 10.1001/jamainternmed.2020.0146 · DOI
  36. 2018, Strategic communication: defining the field and its contribution to research and Practice, International Journal of Strategic Communication, 12, 487, 10.1080/1553118X.2018.1493485 · DOI
  37. 2020, Drug utilization and drug pricing in the private primary healthcare system in malaysia: an employer price control mechanism, Frontiers in Public Health, 8, 1

Cited by

See all 12

Metadata

Authors
Ashraf, A., & Ong, S. C.
Affiliations
Universiti Sains Malaysia (MY)
ORCID
Venue
International Journal of Health Governance
Publisher
Emerald
Published
2021-08-24
Volume
26
Issue
4
Pages
333-347
ISSN
2059-4631 (ISSN-L)
DOI
10.1108/ijhg-02-2021-0014
OpenAlex
W3195182961
Cited by
12
References
0
Citations by year
2026: 1 · 2024: 1 · 2023: 6 · 2022: 3 · 2021: 1
FWCI
2.10
Type
journal article
Language
en
Open access
closed
Licence
www.emerald.com/insight/site-policies (tdm)
Locations
International Journal of Health Governance (publishedVersion)
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Global Public Health Policies and Epidemiology
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
Keywords
drug price regulation, drug pricing, stakeholder analysis, Malaysia, pharmaceutical industry opposition, public sector support, consumer groups, political will, health policy, policy success factors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Drug price control in Malaysia: a stakeholder analysis. https://app.cochat.ai/papers/10.1108/ijhg-02-2021-0014
The paper
Ashraf, A., & Ong, S. C. (2021). Drug price control in Malaysia: a stakeholder analysis. International Journal of Health Governance. https://doi.org/10.1108/ijhg-02-2021-0014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.